Patient Advocacy Grants in the US
Due to the recent news that Oncopeptides has voluntarily withdrawn PEPAXTO® in the U.S. and will close the U.S. commercial business unit, we will not consider any grants for 2022, unfortunately. We sincerely thank you for your support and interest in Oncopeptides and the treatment of patients with relapsed or refractory multiple myeloma.
Oncopeptides is committed to supporting the diverse Multiple Myeloma Community. As such, we consider requests to support activities or initiatives such as grants or sponsorships that support patients with multiple myeloma and their caregivers.
The requests must be aligned with our area of focus and be submitted by non-promotional, healthcare-related organizations such as foundations, professional or scientific associations, and patient advocacy groups by way of patient Education Grants and Corporate Sponsorship for events, activities and initiatives which demonstrate our commitment to patients or communities.
No sponsorship provided by Oncopeptides is conditioned in any way on the use, purchase, prescription or recommendation of any current or future studies or products.